The involvement of a reputable institution like the University of Nebraska Medical Center in enrolling patients for RenovoRx's Phase III clinical trial is likely to accelerate the trial's progress. This can increase investor confidence in the company's ability to advance its treatment for pancreatic cancer, potentially leading to a positive short-term impact on the stock price.